Investigational drug · Phase 2
SPH3127
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Kidney Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
10
Any phase or sponsor naming "SPH3127"
First trial start
2023
Mar 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPH3127", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Kidney Disease
Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SPH3127" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential HypertensionPivotal-lookingCompleted
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05359068 · 957 participants · Start Jun 10, 2021 · Primary completion Dec 26, 2023
Drug: SPH3127 tablet; SPH3127 tablet and 4 more · For: Essential Hypertension
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 40 sites in all
- Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney DiseasePivotal-lookingCompleted
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05593575 · 305 participants · Start Mar 22, 2023 · Primary completion Dec 31, 2024
Drug: SPH3127+SPH3127matching placebo+valsartan matching placebo; SPH3127+SPH3127matching placebo+valsartan matching placebo and 2 more · For: Diabetic Kidney Disease
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 45 sites in all
- Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension PatientsPivotal-lookingCompleted
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT03756103 · 120 participants · Start Jan 11, 2019 · Primary completion Jun 30, 2020
Drug: SPH3127 tablet Dose 1; SPH3127 tablet Dose 2 and 2 more · For: Hypertension,Essential
Sites: Beijing, China; Changsha, China; Chengdu, China · 10 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05770609 · 53 participants · Start Jun 19, 2023 · Primary completion Sep 13, 2024
Drug: SPH3127 Tablets with Dose A; SPH3127 Tablets with Dose B and 1 more · For: Mild to Moderate Ulcerative Colitis
Sites: Guangzhou, China; Huizhou, China; Zhengzhou, China · 25 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT03128138 · 48 participants · Start Dec 1, 2016 · Primary completion Jun 30, 2018
Drug: SPH3127 · For: Hypertension
Sites: Beijing, China
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05359055 · 40 participants · Start Dec 13, 2021 · Primary completion Jan 21, 2022
Drug: SPH3127 tablet; Itraconazole and 2 more · For: Drug Drug Interaction
Sites: Chengdu, China
- The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy PeopleCompleted
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT03255993 · 24 participants · Start Oct 23, 2017 · Primary completion Sep 20, 2018
Drug: SPH3127 50mg; SPH3127 100mg and 2 more · For: Hypertension
Sites: Beijing, China
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT03249753 · 20 participants · Start Sep 23, 2017 · Primary completion Sep 30, 2018
Drug: SPH3127 200mg Panel A; SPH3127 200mg Panel B · For: Hypertension
Sites: Beijing, China
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05593562 · 6 participants · Start Oct 16, 2022 · Primary completion Oct 24, 2022
Drug: SPH3127 · For: Primary Mild and Moderate Hypertension
Sites: Suzhou, China
Shanghai Pharma Biotherapeutics USA Inc.Industry
NCT05019742 · 3 participants · Start Mar 21, 2022 · Primary completion Nov 1, 2022
Drug: SPH3127; Placebo · For: Ulcerative Colitis
Sites: Huntsville, Alabama; Los Angeles, California; Mission Hills, California · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics, mass balance, and metabolism of [14C]SPH3127 (sitokiren), a novel direct renin inhibitor in humans.
Ma S, Huang X, Yan S, et al. · Front Pharmacol 2026
- Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial.
Lv Q, Ma C, Wang F, et al. · Drugs 2026
- SPH3127 (Sitokiren), a Novel Renin Inhibitor, Suppresses Colitis Development in Mouse Models of Experimental Colitis.
Liu W, Wang L, Muefong C, et al. · Inflamm Bowel Dis 2025
- A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension.
Wang F, Liu L, Ruan H, et al. · Hypertens Res 2024
- Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor.
Iijima D, Sugama H, Takahashi Y, et al. · J Med Chem 2022
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial.
Jing S, Xu R, Yang K, et al. · Clin Ther 2021
Also in development for Diabetic Kidney Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.